Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial.

ABSTRACT:

Importance

Parenteral enoxaparin is a preferred anticoagulant used in the acute phase for patients with acute coronary syndrome (ACS). The safety and efficacy of short-term low-dose rivaroxaban in this clinical setting remain unknown.

Objective

To compare the safety and efficacy of rivaroxaban vs enoxaparin in the acute phase of ACS.

Design, setting, and participants

This multicenter, prospective, open-label, active-controlled, equivalence and noninferiority trial was conducted from January 2017 through May 2021 with a 6-month follow-up at 21 hospitals in China. Participants included patients with ACS missing the primary reperfusion window or before selective revascularization. Data were analyzed from November 2021 to November 2022.

Interventions

Participants w

SUBMITTER: Zhou S 

PROVIDER: S-EPMC9918885 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature